866-997-4948(US-Canada Toll Free)

Diabetes - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Sep 2012

Category :

Diabetes

No. of Pages : 127 Pages


Diabetes Pipeline Review, H2 2012

Global Markets Directs, \'Diabetes Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetes. 

Diabetes Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetes.
  • A review of the Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetes pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetes.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetes pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetes Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diabetes 10
Diabetes Therapeutics under Development by Companies 12
Diabetes Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Diabetes Therapeutics Products under Development by Companies 25
Diabetes Therapeutics Products under Investigation by Universities/Institutes 33
Companies Involved in Diabetes Therapeutics Development 34
Bristol-Myers Squibb Company 34
Baxter International Inc. 35
F. Hoffmann-La Roche Ltd. 36
Sanofi-Aventis 37
Eli Lilly and Company 38
Athersys, Inc. 39
Daiichi Sankyo Company, Ltd 40
Euroscreen S.A. 41
Cytokine PharmaSciences, Inc. 42
Takeda Pharmaceutical Company Limited 43
Meytav Technological Incubator 44
Ipsen S.A. 45
Piramal Healthcare Limited 46
Amylin Pharmaceuticals, Inc. 47
Astellas Pharma Inc. 48
Biocon Limited 49
Rigel Pharmaceuticals, Inc. 50
Sigma-Tau S.p.A. 51
Zydus Cadila Healthcare Limited 52
Biodel Inc. 53
Halozyme Therapeutics 54
Access Pharmaceuticals, Inc. 55
Genfit 56
Ligand Pharmaceuticals Incorporated 57
Lupin Limited 58
NexMed, Inc. 59
Oramed Pharmaceuticals, Inc. 60
Orchid Chemicals & Pharmaceuticals Ltd 61
Yuhan Corporation 62
Array BioPharma Inc. 63
XOMA Ltd. 64
Torrent Pharmaceuticals Limited 65
Choongwae Pharma Corp 66
Hanall Pharmaceutical Co., Ltd. 67
HYUNDAI PHARM. CO., LTD. 68
Suven Life Sciences Ltd. 69
Galapagos NV 70
Proximagen Neuroscience plc. 71
Transgene Biotek Ltd 72
Angelini Group 73
Betagenon AB 74
Biotecnol SA 75
Jenrin Discovery, Inc. 76
Phosphagenics Limited 77
Xenon Pharmaceuticals Inc. 78
Spherix Incorporated 79
Ambrx, Inc. 80
Five Prime Therapeutics, Inc. 81
GP Pharm, S.A. 82
Conatus Pharmaceuticals Inc. 83
MSM Protein Technologies, Inc. 84
Zealand Pharma A/S 85
Indus Biotech Private Limited 86
Theracos, Inc. 87
Vantia Therapeutics 88
Omeros Corporation 89
Aegis Therapeutics, LLC 90
Peptron, Inc. 91
Immunocore Limited. 92
Kalypsys, Inc. 93
PepTcell Limited 94
Limerick BioPharma, Inc. 95
Glucox Biotech 96
Diakron Pharmaceuticals, Inc. 97
Verva Pharmaceuticals Limited 98
Adocia 99
Amplimmune, Inc. 100
Ascendis Pharma A/S 101
Signum Biosciences, Inc. 102
PharmaIN Corporation 103
AUS Bio Limited 104
Advancell 105
Rhythm Pharmaceuticals 106
Diabetes Therapeutics Assessment 107
Assessment by Monotherapy Products 107
Assessment by Combination Products 108
Drug Profiles 109
insulin detemir - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Insulin glargine recombinant - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
sitagliptin phosphate - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Research and Development Brief 113
metreleptin - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Research and Development Brief 114
Licensing and Collaboration 114
Other Developmental Activities 114
desmopressin acetate - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Diabetes Therapeutics Drug Profile Updates 116
Diabetes Therapeutics Discontinued Products 118
Diabetes Therapeutics - Dormant Products 121

Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 126
Contact Us 127
Disclaimer 127

List of Table


Number of Products Under Development for Diabetes, H2 2012 10
Products under Development for Diabetes Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Number of Products under Development by Companies, H2 2012 (Contd..2) 15
Number of Products under Development by Companies, H2 2012 (Contd..3) 16
Number of Products under Development by Companies, H2 2012 (Contd..4) 17
Number of Products under Development by Companies, H2 2012 (Contd..5) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Comparative Analysis by Late Stage Development, H2 2012 21
Comparative Analysis by Mid Clinical Stage Development, H2 2012 22
Comparative Analysis by Early Clinical Stage Development, H2 2012 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Development by Companies, H2 2012 (Contd..1) 26
Products under Development by Companies, H2 2012 (Contd..2) 27
Products under Development by Companies, H2 2012 (Contd..3) 28
Products under Development by Companies, H2 2012 (Contd..4) 29
Products under Development by Companies, H2 2012 (Contd..5) 30
Products under Development by Companies, H2 2012 (Contd..6) 31
Products under Development by Companies, H2 2012 (Contd..7) 32
Products under Investigation by Universities/Institutes, H2 2012 33
Bristol-Myers Squibb Company, H2 2012 34
Baxter International Inc., H2 2012 35
F. Hoffmann-La Roche Ltd., H2 2012 36
Sanofi-Aventis, H2 2012 37
Eli Lilly and Company, H2 2012 38
Athersys, Inc., H2 2012 39
Daiichi Sankyo Company, Ltd, H2 2012 40
Euroscreen S.A., H2 2012 41
Cytokine PharmaSciences, Inc., H2 2012 42
Takeda Pharmaceutical Company Limited, H2 2012 43
Meytav Technological Incubator, H2 2012 44
Ipsen S.A., H2 2012 45
Piramal Healthcare Limited, H2 2012 46
Amylin Pharmaceuticals, Inc., H2 2012 47
Astellas Pharma Inc., H2 2012 48
Biocon Limited, H2 2012 49
Rigel Pharmaceuticals, Inc., H2 2012 50
Sigma-Tau S.p.A., H2 2012 51
Zydus Cadila Healthcare Limited, H2 2012 52
Biodel Inc., H2 2012 53
Halozyme Therapeutics, H2 2012 54
Access Pharmaceuticals, Inc., H2 2012 55
Genfit, H2 2012 56
Ligand Pharmaceuticals Incorporated, H2 2012 57
Lupin Limited, H2 2012 58
NexMed, Inc., H2 2012 59
Oramed Pharmaceuticals, Inc., H2 2012 60
Orchid Chemicals & Pharmaceuticals Ltd, H2 2012 61
Yuhan Corporation, H2 2012 62
Array BioPharma Inc., H2 2012 63
XOMA Ltd., H2 2012 64
Torrent Pharmaceuticals Limited, H2 2012 65
Choongwae Pharma Corp, H2 2012 66
Hanall Pharmaceutical Co., Ltd., H2 2012 67
HYUNDAI PHARM. CO., LTD., H2 2012 68
Suven Life Sciences Ltd., H2 2012 69
Galapagos NV, H2 2012 70
Proximagen Neuroscience plc., H2 2012 71
Transgene Biotek Ltd, H2 2012 72
Angelini Group, H2 2012 73
Betagenon AB, H2 2012 74
Biotecnol SA, H2 2012 75
Jenrin Discovery, Inc., H2 2012 76
Phosphagenics Limited, H2 2012 77
Xenon Pharmaceuticals Inc., H2 2012 78
Spherix Incorporated, H2 2012 79
Ambrx, Inc., H2 2012 80
Five Prime Therapeutics, Inc., H2 2012 81
GP Pharm, S.A., H2 2012 82
Assessment by Monotherapy Products, H2 2012 107
Assessment by Combination Products, H2 2012 108
Diabetes Therapeutics Drug Profile Updates 116
Diabetes Therapeutics Discontinued Products 118
Diabetes Therapeutics Discontinued Products (Contd..1) 119
Diabetes Therapeutics Discontinued Products (Contd..2) 120
Diabetes Therapeutics Dormant Products 121
Diabetes Therapeutics Dormant Products (Contd..1) 122
Diabetes Therapeutics Dormant Products (Contd..2) 123
Diabetes Therapeutics Dormant Products (Contd..3) 124
Diabetes Therapeutics Dormant Products (Contd..4) 125

List of Chart


Number of Products under Development for Diabetes, H2 2012 10
Products under Development for Diabetes Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 21
Mid Clinical Stage Products, H2 2012 22
Early Clinical Stage Products, H2 2012 23
Discovery and Pre-Clinical Stage Products, H2 2012 24
Assessment by Monotherapy Products, H2 2012 107
Assessment by Combination Products, H2 2012 108

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *